Introduction
============

Esophageal cancer is the sixth leading cause of cancer-related mortality. It caused the mortality of 440,000 people in 2013([@b1-etm-0-0-8697]). It is the third deadliest cancer in Chinese males and the fifth deadliest malignance in Chinese females ([@b2-etm-0-0-8697]). In China and other Asian countries, 95% of the esophageal cancer is esophageal squamous cell carcinoma (ESCC) and the 5-year overall survival rate is \~10-20% ([@b3-etm-0-0-8697]). Therefore, it is important to identify the tumor-specific markers in ESCC ([@b4-etm-0-0-8697]).

Histone deacetylases (HDACs) are expressed in plants, animals, fungi, archaebacteria and eubacteria ([@b5-etm-0-0-8697]). HDACs are classified into Class I, II and IV or Class III (coenzyme-nicotinamide adenine dinucleotide). HDAC1, -2, -3 and -8 belong to Class I ([@b6-etm-0-0-8697]). HDACs together with histone acetylases can regulate gene transcription and carcinogenesis by modulating chromatin structure ([@b7-etm-0-0-8697]). Class I HDACs have been shown to be widely expressed in all kinds of solid cancers ([@b8-etm-0-0-8697],[@b9-etm-0-0-8697]). HDAC1 expression in ESCC is higher compared with normal esophageal mucosa. When cancer cells invade the deep layer of the esophageal wall, the expression of HDAC 1 is significantly decreased compared with normal control samples ([@b10-etm-0-0-8697]). Nevertheless, the expression and role of HDAC2 and 3 in ESCC remain to be elucidated.

The relationship between histone deacetylation and cellular events, including cell proliferation, differentiation and cell cycle regulation has been demonstrated ([@b11-etm-0-0-8697]). For example, HDACs may inhibit target gene expression by binding to the transcriptional cofactor PC3/Tis21, thereby inhibiting cell proliferation ([@b14-etm-0-0-8697]). HDAC2 overexpression enhances the aggressiveness of gastric carcinoma cells and HDAC2 inhibition attenuates the carcinogenic potential of gastric carcinoma cells in xenotransplanted nude mice ([@b13-etm-0-0-8697]). In addition, several studies have shown that HDAC3 is over-expressed in various solid tumors and is closely associated with poor prognosis ([@b14-etm-0-0-8697]).

The present study investigated the expression levels of HDAC1, -2 and -3 and their clinical significance in ESCC. The association of HDAC1, -2 and -3 with clinicopathological characteristics of ESCC was also analyzed.

Materials and methods
=====================

### Patient information and tissue specimens

Primary ESCC tissues and paired distal normal tissues (\>5 cm away from the margin of tumor tissue) were collected from 88 patients (Kazak, n=40; Han, n=44). Esophagus excision was performed between December 2009 and September 2015 at the Xinjiang Medical University Affiliated Cancer Hospital. No patient received preoperative chemotherapy or radiotherapy. ESCC diagnosis was confirmed by pathology. Patient characteristics including sex, age, lymph node (LN) metastasis, differentiation and depth of invasion were recorded ([Table I](#tI-etm-0-0-8697){ref-type="table"}). The present study research was approved by the Ethics Committee of Xinjiang Medical University and all patients provided written informed consent.

### Reverse transcription semi-quantified PCR

Total RNA was extracted with TRIzol (Invitrogen, Thermo Fisher Scientific, Inc.) from ESCC tissues and paired distal normal tissues. Reverse transcription of RNA was performed with avian myeloblastosis virus reverse transcriptase (Promega Corporation). Reverse transcription was performed under the following heat conditions: 55˚C for 90 min and 4˚C for 10 min. The cDNA products were identified on a 2% agarose gel with ethidium bromide. The PCR reaction system included 2 µl reverse-transcribed cDNA, 10 µl 2XPCR master mix, 1 µl of each primer (10 µM) and 6 µl ddH~2~O (Ready-to-Use PCR kit, Beijing Transgen Biotech Co., Ltd.). Amplification was performed on an iCycler^™^ Thermal Cycler (Bio-Rad Laboratories, Inc.). GAPDH was an internal control.

The PCR primers were: *HDAC1* forward, 5\'-AGTGCGGTGGTCTTACAGTG-3\', *HDAC1* reverse, 5\'-TCTCCCTCCTCTTCAGAATCG-3\', *HDAC2* forward, 5\'-GCTGGTCTTGAACTCCTT-3\', *HDAC2* reverse, 5\'-TACAACCCATCTGGCATC-3\', *HDAC3* forward, 5\'-GGGACATTATTGGCAGTG-3\', *HDAC3* reverse, 5\'-GGATTCAGGTGTTAGGGAG-3\', *GAPDH* forward, 5\'-GCGGGCTCTCCAGAACATCAT-3\' and *GAPDH* reverse, 5\'-CCAGCCCCAGCGTCAAAGGTG-3\'. The thermocyling conditions were as follows: Initial denaturation at 95˚C for 5 min; 35 cycles of 95˚C for 30 sec, 58˚C for 20 sec for *HDAC1*. 54˚C for 20 sec for *HDAC2*, 58˚C for 30 sec for *HDAC3* and 60˚C for 30 sec for *GAPDH*, 72˚C for 30s; and a final extension at 72˚C for 7 min. The PCR products were identified on a 1.5% agarose gel with ethidium bromide and analyzed with the Gel Doc XR System (Bio-Rad Laboratories, Inc.). The DNA ladder maker was purchased from Sangon Biotech Co., Ltd. The intensities of PCR product bands were quantified using Quantity One software version 4.5.2 (Bio-Rad Laboratories, Inc.). The quantity of each PCR product band was standardized to that of *GAPDH*. The presence or absence of bands was considered positive or negative. Grey scale ratio \>2 was defined as high expression.

### Statistical analysis

SPSS 17.0 software (SPSS Inc.) was used for data analysis. Experiments were performed in triplicate. Measurement data were presented as the mean ± SD. Count data were expressed as the number (%). Correlations among HDAC1, -2 and -3 expression were analyzed by the Pearson correlation test. Differences in gene expression were analyzed using a paired t-test and variances in clinicopathologic features were analyzed using χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

First, the basic information of the patients was investigated ([Table I](#tI-etm-0-0-8697){ref-type="table"}). Of the 88 patients, 26 (29.5%) were women and 62 (70.5%) were men. Their mean age was 58.2 years, 37-84 years old. The most common tumor location was at the middle and lower esophagus (95.5%). There were 69 ESCC cases with moderate to high differentiation and 19 with poor differentiation. A total of 46 cases had LN metastasis and 42 did not have LN metastasis. There were 13 cases of T~1~+T~2~ and 75 cases of T~3~+T~4.~

### Expression levels of HDAC1, -2 and -3 in human ESCC and distal normal tissues

To compare the expression levels of *HDAC1, -2* and *-3* in tumor issues and distal normal tissues, reverse transcription semi-quantified PCR analysis was performed. The representative amplification results of *HDAC1, -2* and *-3* are presented in [Fig. 1A](#f1-etm-0-0-8697){ref-type="fig"}. It demonstrated that *HDAC1* was 510 bp in length, *HDAC2* was 187 bp, *HDAC3* was 233 bp and *GAPDH* was 309 bp ([Fig. 1A](#f1-etm-0-0-8697){ref-type="fig"}). Following quantification, expression of *HDAC1*, *-2* and -3 mRNA was elevated in tumor tissues compared with distal normal tissue, although no significant difference was observed ([Fig. 1B](#f1-etm-0-0-8697){ref-type="fig"}). The *HDAC1* mRNAs were positive in 48.9% (43/88) of the tumor tissues, *HDAC2* mRNAs were positive in 77.3 (68/88) of the tumor tissues and *HDAC3* mRNAs were positive in 93.2% (82/88) of the tumor tissues. Their positive rate in distal normal tissues was 31.8% (28/88), 85.2% (75/88) and 87.5% (77/88), respectively. The expression of *HDAC1*, but not *HDAC2* or *HDAC3*, was higher in ESCC samples than in distal normal samples (P\<0.05; [Table II](#tII-etm-0-0-8697){ref-type="table"}). The expression of *HDAC1*, *-2* and -3 in patients of different ethnicities was also analyzed. As shown in [Table III](#tIII-etm-0-0-8697){ref-type="table"}, the expression of *HDAC1* in tumor tissue and normal tissue of Kazak people was lower compared with Han people (P\<0.05). The expression of *HDAC2* in normal tissue of Kazak people was decreased compared with that in Han people. The expression of *HDAC3* in tumor tissue of Kazak people was decreased compared with that in Han people (P\<0.05).

### Relationship of HDAC1, -2 and -3 expression with clinicopathological characteristics

Next the relationship of HDAC1, -2 and -3 expression with the clinicopathological characteristics of ESCC patients was detected. No significant differences were found in correlation analysis between HDAC1 expression and clinicopathological indexes ([Table IV](#tIV-etm-0-0-8697){ref-type="table"}). The expression of HDAC2 was significantly related with invasion depth (P\<0.05; [Table V](#tV-etm-0-0-8697){ref-type="table"}). However, there were no significant correlation between HDAC2 and age, sex, depth of invasion and tumor differentiation. Moreover, no significant differences were found between HDAC3 expression and clinicopathological indexes ([Table VI](#tVI-etm-0-0-8697){ref-type="table"}). For the Kazak and Han ethnicities, the expression of HDAC1 in male patients, patients with well and moderate differentiated ESCC and T3 and T4 ESCC were significantly related with ethnicity (P\<0.01; [Table VII](#tVII-etm-0-0-8697){ref-type="table"}). The expression of HDAC1 in patients less than 60 years old was related with ethnicity (P\<0.05; [Table VII](#tVII-etm-0-0-8697){ref-type="table"}). The expression of HDAC2 in positive LN metastasis, well and moderate differentiation and T3 and T4 stages were significantly related with ethnicity (P\<0.01; [Table VIII](#tVIII-etm-0-0-8697){ref-type="table"}). The expression of HDAC2 in female patients and negative LN metastasis were related with ethnicity (P\<0.05; [Table VIII](#tVIII-etm-0-0-8697){ref-type="table"}). The expression of HDAC3 in male, negative LN metastasis and well and moderate differentiation was related with ethnicity (P\<0.05; [Table IX](#tIX-etm-0-0-8697){ref-type="table"}).

### Correlation among HDAC1, -2 and -3 expression in human ESCC tissues

The correlation among HDAC1, -2 and -3 was obtained by using Pearson\'s correlation test. The result showed that there were no significant correlations between HDAC1 and HDAC2 (r=-0.042, P=0.694), HDAC1 and HDAC3 (r=-0.084, P=0.430), or HDAC2 and HDAC3 (r=-0.176, P=0.099) in ESCC tissues ([Fig. 2](#f2-etm-0-0-8697){ref-type="fig"}). These results indicated that there was no correlation among the three HDACs.

Discussion
==========

ESCC is a common malignant cancer, which can easily invade adjacent areas and metastasize to lymph nodes and distant tissues ([@b15-etm-0-0-8697],[@b16-etm-0-0-8697]). It has a high degree of prevalence and a low survival rate. Thus, it is urgent to develop molecular markers that can facilitate the early detection of ESCC.

HDAC1 contains 482 amino acids, identified in 1996 by Taunton *et al* ([@b17-etm-0-0-8697]). HDAC1 regulates genes involved in cell differentiation and the cell cycle, and participates in the development of various diseases such as viral infectious diseases, degenerative diseases and cancer ([@b18-etm-0-0-8697]). HDAC1 can mediate site-specific DNA-binding transcriptional repression and a high level of HDAC1 is observed in tumor invasion and metastasis ([@b21-etm-0-0-8697]). Burdelski *et al* ([@b22-etm-0-0-8697]) identified that a high level of HDAC1 was associated with high Gleason grade, advanced pathological tumor stage, positive LN metastasis, elevated preoperative prostate specific antigen level and cell proliferation; therefore, HDAC1 expression detection may have clinical significance for the risk stratification of prostate cancer. Huang *et al* ([@b23-etm-0-0-8697]), demonstrated high expression of HDACs in cervical cancer and cervical intraepithelial neoplasia tissues. Mutze *et al* ([@b24-etm-0-0-8697]), identified high levels of HDAC1 and HDAC2 in gastric carcinomas and they were not related to the response to platinum/5-fluorouracil. High HDAC1 level is related to lower overall survival ([@b25-etm-0-0-8697]). There is a significant association between HDAC1 high expression and advanced age ([@b26-etm-0-0-8697]). High levels of HDAC1 expression are associated with a poor histological differentiation and prognosis in liver cell carcinoma ([@b27-etm-0-0-8697]). There is higher expression of HDAC1 in gastrointestinal malignant tumor, particularly in colorectal cancer and HDAC1 expression is closely related to clinical characteristics of gastrointestinal cancer ([@b8-etm-0-0-8697]). Zhong *et al* ([@b28-etm-0-0-8697]), noted that the high expression of HDAC1 may serve as a potential therapeutic target for ESCC. Miyashita *et al* ([@b29-etm-0-0-8697]), reported that the expression of HDAC1 may be involved in duodenoesophageal reflux-induced neoplastic transformation of the esophageal mucosa into cancer cells with squamous and adeno differentiation. By contrast, Langer *et al* ([@b30-etm-0-0-8697]) stated HDAC1 expression is not changed based on pT, pN category or esophageal adenocarcinoma differentiation level. Xu *et al* ([@b31-etm-0-0-8697]), noted that HERG1 contributes to poor prognosis of ESCC and suggest that targeting HERG1 may have potential diagnostic and therapeutic value for ESCC treatment. In the present study, the positive rate of HDAC1 expression in ESCC was increased compared with normal tissues. However, the expression did not change according to sex, age, metastasis, differentiation degree and invasion depth.

HDAC2 can promote tumorigenesis through several mechanisms, including promoting the degradation of β-catenin and decreasing epigenetic modification ([@b15-etm-0-0-8697],[@b32-etm-0-0-8697]). In addition, HDAC2 can inhibit the expression of tumor suppressor p53 and p21 while promoting expression of oncogene Myc ([@b33-etm-0-0-8697],[@b34-etm-0-0-8697]). HDAC2 participates in chronic obstructive pulmonary disease ([@b35-etm-0-0-8697],[@b36-etm-0-0-8697]). It is also over expressed in lung cancer ([@b37-etm-0-0-8697]). Huang *et al* ([@b40-etm-0-0-8697]), demonstrated that HDAC2 affects chromatin remodeling following DNA damage in ovarian cancer cells. It is also reported that high HDAC2 expression indicates high aggressive behavior in esophageal adenocarcinoma ([@b30-etm-0-0-8697]). Wang *et al* ([@b41-etm-0-0-8697]), noted that the level of HDAC2 increases dramatically in ESCC compared with adjacent non-tumor tissues. Li *et al* ([@b42-etm-0-0-8697]) reported that the HDAC2 protein level in ESCC tissues was significantly increased and was closely associated with the histological grade, invasion depth and lymph node metastasis. Göder *et al* ([@b43-etm-0-0-8697]) noted that HDAC1 and HDAC2 regulate checkpoint kinase phosphorylation through suppression of PR130. HDACi, as well as an elimination of HDAC1/HDAC2, induces PR130-dependent mechanisms that inhibit checkpoint kinase phosphorylation. However, the present study failed to detect notable changes in HDAC2 expression between ESCC and normal tissues. However, the expression of HDAC2 was related to the invasion depth.

HDAC3 is also an essential factor for cell survival and proliferation in tumors and in maintaining the structure of chromatin and the stability of genome ([@b44-etm-0-0-8697]). HDAC3 can form large corepressor complexes with N-CoR and SMRT ([@b45-etm-0-0-8697]). High HDAC3 expression has been found in colon or gastric tumor cells and it has an antiapoptotic function ([@b46-etm-0-0-8697],[@b47-etm-0-0-8697]). High expression of HDAC3 is also noted in gastric cancer, where it is associated with poor prognosis ([@b14-etm-0-0-8697]). HDAC3 stimulates cell migration of ovarian carcinoma and high HDAC3 expression indicates poor prognosis of lung adenocarcinoma patients ([@b48-etm-0-0-8697],[@b49-etm-0-0-8697]). Jiao *et al* ([@b50-etm-0-0-8697]) found that increased HDAC3 level in the nucleus, but not in the cytoplasm, was related with LN metastasis and advanced clinical staging of pancreatic cancer. It has also been reported that HDAC3 is a risk factor of ESCC and may be used to evaluate the grade of malignancy and prognosis of ESCC ([@b51-etm-0-0-8697]). The present study found no significant difference in the expression of HDAC3 in ESCC tissue compared with normal tissue and identified that the expression of HDAC3 was not associated with sex, age, metastasis, degree of esophageal tissue differentiation or the depth of invasion. It was hypothesized that perhaps regional differences and ethnic specificity lead to the discrepancy between the present results and a previous study ([@b51-etm-0-0-8697]). These results indicate that the expression of HDAC3 has no relationship with the development of ESCC.

Additionally, the present study found that the expression of HDACs in tumor tissue from Kazak people was lower compared with Han people. In ESCC, the positive rate of HDAC1 expression in ESCC tissues was increased compared with normal tissue. The expression of HDAC2 varied according to the invasion depth of ESCC patients. However, HDAC3 showed no significant expression changes in ESCC and was not correlated with the clinicopathological characteristics of ESCC patients. The expression of HDACs in tumor tissue of Kazak people was lower compared with Han people. Additionally, it was noted that the expression of HDAC1, -2 and -3 had ethnic differences.

As for treatment, Ahrens *et al* ([@b52-etm-0-0-8697]) proposed that targeting epigenetic modifiers in esophageal cancers may represent a potential future therapeutic approach. Kano *et al* ([@b53-etm-0-0-8697]) found that CHAP31 sensitized SCC cells to carbon-ion radiotherapy and this combination treatment may be a potentially useful therapeutic strategy for ESCC. Hoshino *et al* ([@b54-etm-0-0-8697]) suggested that HDACi-FK228 has a potent ability to augment the effect of adenovirus-mediated p53 gene therapy in ESCC. Thus, targeting HDACs may be an effective approach for treatment of ESCC.

In summary, HDAC1 may be used as a risk factor for ESCC and HDAC2 may be used to predict ESCC invasion. The different clinical parameter expression is related to ethnic differences. Future research should focus on the effect of HDAC inhibitors on ESCC treatment in Xinjiang, China.
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![Expression of *HDAC1*, *-2* and *-3* mRNA. *HDAC1, -2* and *-3* mRNA levels in ESCC samples and normal tissues were analyzed by semi-quantified PCR. (A) Representative amplification results of *HDAC1, -2* and *-3* in patient specimens. (B) Normalized *HDAC1*, *-2* and *-3* expression level in human ESCC and normal tissues. T, primary tumor; N, paired normal tissues; M, marker; ESCC, esophageal squamous cell carcinoma; HDAC, histone deacetylase.](etm-20-01-0315-g00){#f1-etm-0-0-8697}

![Correlation of *HDAC1*, *-2* and *-3* expression in human esophageal squamous cell carcinoma (n=88). Pearson\'s correlation test was used to analyze the correlation among *HDAC1*, *-2* and *-3*. HDAC, histone deacetylase.](etm-20-01-0315-g01){#f2-etm-0-0-8697}

###### 

Clinicopathological characteristics of esophageal squamous cell carcinoma patients.

  Basic data               Number
  ------------------------ --------
  Sex                      
       Male                62
       Female              26
  Ethnicity                48
       Han                 40
       Kazakh              
  Age                      
       \<60 yrs            46
       ≥60 yrs             42
  LN Metastasis            
       Positive            46
       Negative            42
  Differentiation          
       Well and Moderate   69
       Poor                19
  Depth of invasion        
       T1 and T2           13
       T3 and T4           75

ESCC, esophageal squamous cell carcinoma; LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs.

###### 

Expression of *HDAC1*, *-2* and *-3* mRNA in tumor and normal tissue.

  Expression of mRNA   Specimens   No   Positive (+)   Negative (-)   Positive rate (%)   *X*^2^   P-value
  -------------------- ----------- ---- -------------- -------------- ------------------- -------- -----------------------------------------------------
  *HDAC1*              T           88   43             45             48.9 (43/88)        5.312    0.021^[a](#tfn1-etm-0-0-8697){ref-type="table-fn"}^
                       N           88   28             60             31.8 (28/88)                 
  *HDAC2*              T           88   68             20             77.3 (68/88)        1.828    0.176
                       N           88   75             13             85.2 (75/88)                 
  *HDAC3*              T           88   82             6              93.2 (82/88)        1.628    0.202
                       N           88   77             11             87.5 (77/88)                 

^a^P\<0.05. T, Tumor tissues; N, Normal tissues; HDAC, histone deacetylase.

###### 

Expression of *HDAC1*, *HDAC2* and *HDAC3* mRNA in tumor and normal tissue of Han and Kazak people.

  Expression of mRNA   Specimens   Positive no. (+)   Negative no. (-)   *X*^2^   P-value                         
  -------------------- ----------- ------------------ ------------------ -------- --------- ------- ---- -------- -----------------------------------------------------
  *HDAC1*              T           43                 Han                31       45        Han     17   10.443   0.001^[a](#tfn2-etm-0-0-8697){ref-type="table-fn"}^
                                                      Kazak              12                 Kazak   28            
                       N           28                 Han                21       60        Han     27   6.930    0.008^[a](#tfn2-etm-0-0-8697){ref-type="table-fn"}^
                                                      Kazak              7                  Kazak   33            
  *HDAC2*              T           68                 Han                44       20        Han     4    12.458   0.176
                                                      Kazak              24                 Kazak   16            
                       N           75                 Han                46       13        Han     3    6.571    0.010^[a](#tfn2-etm-0-0-8697){ref-type="table-fn"}^
                                                      Kazak              29                 Kazak   10            
  *HDAC3*              T           82                 Han                48       6         Han     0    7.727    0.005^[a](#tfn2-etm-0-0-8697){ref-type="table-fn"}^
                                                      Kazak              34                 Kazak   6             
                       N           77                 Han                45       11        Han     3    3.771    0.052
                                                      Kazak              32                 Kazak   8             

^a^P\<0.05. T, Tumor tissues; N, Normal tissues; HDAC, histone deacetylase.

###### 

Correlation of *HDAC1* expression with clinicopathologic characteristics of esophageal squamous cell carcinoma patients (n=88).

                                Expression of *HDAC1* mRNA                                
  ------------------------ ---- ---------------------------- ---- --------------- ------- -------
  Sex                                                                                     
       Male                62   31                           31   50.0 (31/62)    0.108   0.742
       Female              26   12                           14   46.2 (12/26)            
  Age                                                                                     
       \<60 yrs            46   20                           26   43.5 (20/46)    1.119   0.290
       ≥60 yrs             42   23                           19   54.8 (23/42)            
  LN Metastasis                                                                           
       Positive            46   22                           24   47.8 (22/46)    0.042   0.839
       Negative            42   21                           21   50.0 (21/42)            
  Differentiation                                                                         
       Well and Moderate   69   36                           33   52.26 (36/69)   1.401   0.236
       Poor                19   7                            12   36.8 (7/19)             
  Depth of invasion                                                                       
       T1 and T2           13   6                            7    46.2 (6/13)     0.045   0.832
       T3 and T4           75   37                           38   49.3 (37/75)            

LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

###### 

Correlation of *HDAC2* expression with clinicopathologic characteristics of esophageal squamous cell carcinoma patients (n=88).

  Clinicopathological characteristics   No.   Expression of *HDAC2* mRNA   *X*^2^   P-value                
  ------------------------------------- ----- ---------------------------- -------- -------------- ------- -----------------------------------------------------
  Sex                                                                                                      
       Male                             62    47                           15       75.8 (47/62)   0.257   0.612
       Female                           26    21                           5        80.8 (21/26)           
  Age                                                                                                      
       \<60 yrs                         46    37                           9        80.4 (37/46)   0.549   0.459
       ≥60 yrs                          42    31                           11       73.8 (31/42)           
  LN Metastasis                                                                                            
       Positive                         46    39                           7        84.8 (39/46)   3.095   0.079
       Negative                         42    29                           13       69.0 (29/42)           
  Differentiation                                                                                          
       Well and Moderate                69    52                           17       75.4 (52/69)   0.664   0.415
       Poor                             19    16                           3        84.2 (16/19)           
  Depth of invasion                                                                                        
       T1 and T2                        13    6                            7        13             8.411   0.004^[a](#tfn3-etm-0-0-8697){ref-type="table-fn"}^
       T3 and T4                        75    62                           13       75                     

^a^P\<0.05. LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

###### 

Correlation of *HDAC3* expression with clinicopathologic characteristics of esophageal squamous cell carcinoma patients (n=88).

  Clinicopathological characteristics   No.   Expression of *HDAC3* mRNA   *X*^2^   P-value                
  ------------------------------------- ----- ---------------------------- -------- -------------- ------- -------
  Sex                                                                                                      
       Male                             62    59                           3        95.2 (59/62)   1.294   0.255
       Female                           26    23                           3        88.5 (23/26)           
  Age                                                                                                      
       \<60 yrs                         46    45                           1        97.8 (45/46)   3.272   0.070
       ≥60 yrs                          42    37                           5        88.1 (37/42)           
  LN Metastasis                                                                                            
       Positive                         46    43                           3        93.5 (43/46)   0.013   0.908
       Negative                         42    39                           3        92.9 (39/42)           
  Differentiation                                                                                          
       Well and Moderate                69    64                           5        92.8 (64/69)   0.092   0.761
       Poor                             19    18                           1        94.7 (18/19)           
  Depth of invasion                                                                                        
       T1 and T2                        13    13                           0        100 (13/13)    1.116   0.291
       T3 and T4                        75    69                           6        92.0 (69/75)           

LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

###### 

Correlation of *HDAC1* expression with clinicopathologic characteristics of esophageal squamous cell carcinoma in Han and Kazak patients (n=88).

  Clinicopathological characteristics                       Expression No. of *HDAC1* mRNA   *X*^2^   P-value                              
  ------------------------------------- ------------------- -------------------------------- -------- --------- ---- ------- ---- -------- -----------------------------------------------------
  Sex                                   Male                31                               Han      25        31   Han     12   11.328   0.001^[a](#tfn4-etm-0-0-8697){ref-type="table-fn"}^
                                                                                             Kazak    6              Kazak   19            
                                        Female              12                               Han      6         14   Han     5    0.540    0.462
                                                                                             Kazak    6              Kazak   9             
  Age                                   \<60 yrs            20                               Han      11        26   Han     6    4.945    0.026^[a](#tfn4-etm-0-0-8697){ref-type="table-fn"}^
                                                                                             Kazak    9              Kazak   20            
                                        ≥60 yrs             23                               Han      19        19   Han     12   2.036    0.154
                                                                                             Kazak    4              Kazak   7             
  LN Metastasis                         Positive            22                               Han      13        24   Han     10   1.394    0.238
                                                                                             Kazak    9              Kazak   14            
                                        Negative            21                               Han      18        21   Han     7    2.059    0.151
                                                                                             Kazak    3              Kazak   14            
  Differentiation                       Well and moderate   36                               Han      24        33   Han     11   7.654    0.006^[a](#tfn4-etm-0-0-8697){ref-type="table-fn"}^
                                                                                             Kazak    12             Kazak   22            
                                        Poor                7                                Han      6         12   Han     7    1.534    0.216
                                                                                             Kazak    1              Kazak   5             
  Depth of invasion                     T1 and T2           6                                Han      3         7    Han     2    0.627    0.429
                                                                                             Kazak    3              Kazak   5             
                                        T3 and T4           37                               Han      28        38   Han     15   10.044   0.002^[a](#tfn4-etm-0-0-8697){ref-type="table-fn"}^
                                                                                             Kazak    9              Kazak   23            

^a^P-value was considered statistically significant at \<0.05. LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

###### 

Correlation of HDAC2 expression with clinicopathologic characteristics of esophageal squamous cell carcinoma in Han and Kazaks patients (n=88).

  Clinicopathological characteristics                       Expression No. of HDAC1 mRNA   *X*^2^   P-value                             
  ------------------------------------- ------------------- ------------------------------ -------- --------- ---- ------- ---- ------- -----------------------------------------------------
  Sex                                   Male                47                             Han      31        15   Han     6    3.184   0.074
                                                                                           Kazak    16             Kazak   9            
                                        Female              21                             Han      11        5    Han     0    4.540   0.033^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    10             Kazak   5            
  Age                                   \<60 yrs            37                             Han      17        9    Han     0    6.559   0.010^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    20             Kazak   9            
                                        ≥60 yrs             31                             Han      26        11   Han     5    6.198   0.013^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    5              Kazak   6            
  LN Metastasis                         Positive            39                             Han      23        7    Han     0    8.256   0.004^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    16             Kazak   7            
                                        Negative            29                             Han      21        13   Han     4    6.461   0.011^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    8              Kazak   9            
  Differentiation                       Well and moderate   52                             Han      32        17   Han     3    9.874   0.002^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    20             Kazak   14           
                                        Poor                16                             Han      12        3    Han     1    2.030   0.154
                                                                                           Kazak    4              Kazak   2            
  Depth of invasion                     T1 and T2           6                              Han      4         7    Han     1    3.745   0.053
                                                                                           Kazak    2              Kazak   6            
                                        T3 and T4           62                             Han      40        13   Han     3    7.544   0.006^[a](#tfn5-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    22             Kazak   10           

^a^P\<0.05. LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

###### 

Correlation of HDA3 expressions with clinicopathologic characteristics of esophageal squamous cell carcinoma in Han and Kazak patients (n=88).

  Clinicopathological characteristics                       Expression No. of HDAC3 mRNA   *X*^2^   P-value                           
  ------------------------------------- ------------------- ------------------------------ -------- --------- --- ------- --- ------- -----------------------------------------------------
  Sex                                   Male                59                             Han      37        3   Han     0   4.666   0.031^[a](#tfn6-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    22            Kazak   3           
                                        Female              23                             Han      11        3   Han     0   2.487   0.115
                                                                                           Kazak    12            Kazak   3           
  Age                                   \<60 years          45                             Han      17        1   Han     0   0.599   0.439
                                                                                           Kazak    28            Kazak   1           
                                        ≥60 years           37                             Han      28        5   Han     3   0.560   0.454
                                                                                           Kazak    9             Kazak   2           
  LN metastasis                         Positive            43                             Han      22        3   Han     1   0.357   0.550
                                                                                           Kazak    21            Kazak   2           
                                        Negative            39                             Han      25        3   Han     0   4.751   0.029^[a](#tfn6-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    14            Kazak   3           
  Differentiation                       Well and moderate   64                             Han      35        5   Han     0   5.549   0.018^[a](#tfn6-etm-0-0-8697){ref-type="table-fn"}^
                                                                                           Kazak    29            Kazak   5           
                                        Poor                18                             Han      13        1   Han     0   2.287   0.130
                                                                                           Kazak    5             Kazak   1           
  Depth of invasion                     T1 and T2           13                             Han      5         0   Han     0   /       
                                                                                           Kazak    8             Kazak   0           
                                        T3 and T4           69                             Han      41        6   Han     2   1.536   0.215
                                                                                           Kazak    28            Kazak   4           

^a^P\<0.05. LN, lymph node metastases; T1, tumors only invade the lamina propria and submucosa; T2, tumors invade the muscular layer; T3, tumors invade the esophageal fibrous membrane; T4, tumors invade adjacent organs; HDAC, histone deacetylase.

[^1]: *Abbreviations:* ESCC, esophageal squamous cell carcinoma; HDAC, histone deacetylase
